Shire on hold by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell rated Shire Pharmaceuticals at a hold rating as the company looks to strengthen its mature ADHD franchise with NRP104. The company's enthusiasm to switch from Adderall XR to NRP104 is dependent on favorable scheduling, according to the analyst. NRP104 is a collaboration between Shire and New River Pharmaceuticals Inc. Jefferies does not expect NRP104 to get schedule IV; the analyst feels Schedule II is the best it can achieve, in line with other amphetamine products. Shares of the Basingstoke, England-based pharmaceutical company were up $7.76, or 15.71%, at $57.16. (Nasdaq: SHPGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.